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The National Institute on Aging’s Interventions Testing
Program was established to evaluate agents that are
purported to increase lifespan and delay the appearance
of age-related disease in genetically heterogeneous mice.
Up to five compounds are added to the study each year
and each compound is tested at three test sites (The Jackson
Laboratory, University of Michigan, and University of
Texas Health Science Center at San Antonio). Mice in the




nordihydroguaiaretic acid (NDGA). Sample size was
sufficient to detect a 10% difference in lifespan in either sex,
with 80% power, using data from two of the three sites.
Pooling data from all three sites, a log-rank test showed












 0.01) led to
increased lifespan of male mice. Comparison of the pro-
portion of live mice at the age of 90% mortality was used













 0.16) had a signifi-
cant effect in this test. Measures of blood levels of NDGA
or aspirin and its salicylic acid metabolite suggest that the
observed lack of effects of NDGA or aspirin on lifespan
in females could be related to gender differences in drug
disposition or metabolism. Further studies are warranted
to find whether NDGA or aspirin, over a range of doses,
might prove to postpone death and various age-related
outcomes reproducibly in mice.





Both dietary restriction and single-gene dwarfing mutations in
rodents demonstrate that mammalian aging can be retarded








., 2001; Miller, 2001).
Furthermore, dietary additives with the potential for human
application exist. Unfortunately, clinical screening studies for anti-
aging drugs in humans are impractical because of time, cost, and
ethical constraints. Mouse models have a vital place here because



































Dietary additives that delay aging would potentially have a
major effect on human health, an effect far in excess of preventive
measures that affect only individual forms of late-life disease such








., 1990, 2006; Miller,
2002). Even negative data would be useful if based on strong
science. The published literature contains sporadic reports
(Schneider & Reed, 1985; Archer & Harrison, 1996; Schneider
& Miller, 1998) of dietary additives purported to have beneficial
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accepted by the scientific community as a reliable and reproducible









2000), the National Institute on Aging has developed a program,
the Interventions Testing Program (ITP), to evaluate agents that are
considered plausible candidates for delaying aging or preventing
multiple forms of late-life disease in laboratory mice.
The central features of the ITP protocol and the compounds








. (2007), which also presented
an interim analysis of survival data for mice exposed to one of
four agents. Briefly, test agents are nominated by scientists
whose recommendations are reviewed by an expert committee.
Details about the selection process are found at http://
www.nia.nih.gov/ResearchInformation/ScientificResources/
InterventionsTestingProgram.htm.
Studies were simultaneously replicated at three test sites: the
Jackson Laboratory in Bar Harbor, Maine (TJL), the University of
Michigan at Ann Arbor (UM), and the University of Texas Health
Science Center at San Antonio (UT). The protocol uses geneti-
cally heterogeneous mice, the progeny of CB6F1 females bred
to C3D2F1 males, with breeders supplied to each site at the
same time by TJL. Each animal in the test population is thus
genetically unique, but all the animals are full siblings. None of
the four agents in the current report altered mean weights.
Therefore, positive effects on lifespan could not result from
unintended dietary restriction. The ITP standard protocol uses
36 female and 44 male mice in each treatment group, at each
of the three test sites, as well as 72 females and 96 males in
the untreated control group. The extra males compensate for
the larger number of early life deaths of male mice due to
fighting. According to the power calculations, a design of this
size provides 80% power to detect a 10% increase (or decrease)
in mean lifespan with respect to unmanipulated controls of
the same sex, even if data from one of the three test sites are
unavailable.
This article presents the full lifespan analysis of survival data
for mice exposed to one of four agents. Aspirin is a nonsteroidal
anti-inflammatory agent that also has antithrombotic and anti-









2000) and is widely used clinically. Nitroflurbiprofen (NFP) is a









., 2007). Like flurbiprofen, NFP is a nonsteroidal
anti-inflammatory agent showing about an equal inhibitory
potential against the cyclooxygenases, COX-1 and COX-2. Its
nitric oxide-releasing moiety should make the drug safer than
ibuprofen in chronic administration. Nordihydroguaiaretic acid
(NDGA; also called masoprocol) has both antioxidant and anti-
inflammatory properties, and it resembles other polyphenols
that can activate sirtuins and which have shown life-extension













phenyl-N-tert-butyl nitrone (4-OH-PBN) is the 4-hydroxy derivative





a nitrone that is well known in analytical chemistry to trap and
stabilize free radicals. PBN has potent pharmacologic activities










































0.01) led to a significant increase in survival of male mice. Neither
NFP nor 4-OH-PBN altered survival of male mice, and none of the




Survival analysis: NDGA and aspirin increased 
longevity in male (but not female) UM-HET3 mice
 
Figure 1 shows survival, as a function of age, in male mice treated
with each of the four test agents, pooling data across all three
test sites and using a site-stratified log-rank test. Both NDGA
Fig. 1 Survival plots for male mice treated 
with nordihydroguaiaretic acid (NDGA; upper left), 
aspirin (upper right), nitroflurbiprofen (NFP; 
lower left) or 4-OH-PBN (lower right.) Each symbol 
represents an individual mouse dying at the 
age indicated. Log-rank test was used to calculate 
p-values for differences between treated and 
control mice.
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 0.01) led to a significant increase
in survival, but neither NFP nor 4-OH-PBN altered survival of
male mice. None of the four test agents had a significant effect
on survival of female mice (see Fig. S1). The hypothesis that
these agents altered survival to exceptional old age, a surrogate
for maximal lifespan, was evaluated using the method of Wang








., 2004), in each instance by calculation
of the proportion of mice still alive at the age when the pooled
population, including controls and mice in the treatment group,
had reached 90% mortality. This calculation was stratified by
site, so that the proportion of live mice in control and treatment
groups was evaluated separately at each site, with the pooled
counts then combined for the Fisher exact test statistic. For
NDGA, 8.6% of control mice (i.e. 30 of 350) were alive at this









 0.12, does not meet our significance criterion.
A parallel calculation for aspirin treatment found 8.9% of control
males and 13.1% of aspirin-treated males alive at the 90%








 0.16. Median survival
for control mice was 786 days, compared to 881 days (12%
increase) for NDGA and 849 days (8% increase) for aspirin.
 
Subgroup analyses: site-to-site differences in weights 
and survival curves
 
To see if the effects of NDGA or aspirin differed depending on
the site at which the mice were housed, we evaluated life tables
separately for TJL, UM, and UT. Figure 2 presents survival curves
for each of these two interventions, presented by site, for males

















 0.09) at TJL, but there
was no significant effect at UM. Aspirin led to a significant
















0.051), but not at UM. Although these site-specific analyses
have much lower statistical power than the primary analysis
(pooling across sites), the results suggest that the effect of the
agents may depend on site-specific factors. Indeed, there was








 0.0001) in survival of male mice
among the three test sites (Fig. 3A, Table 1), with UM males
living longer than males at either of the other two sites. In con-
trast, there was no difference in survival of female mice among
sites (Fig. 3B, Table 1). We have previously noted site-specific









2007), with mice at UM lighter in weight than mice at either
of the other two sites; these differences among sites in body
weight were, however, seen in both male and female animals.
We have seen equivalent differences in site-specific survival
patterns of male mice, and weight trajectories of both male and
female mice, in independent cohorts of control UM-HET3 mice
involved in subsequent lifespan studies initiated in 2005 (data
not shown), and we can thus conclude that these site-specific
variations reflect replicable disparities in one or more aspects
Fig. 2 Survival plots for male mice treated with either nordihydroguaiaretic acid (NDGA; top panels) or aspirin (bottom panels), compared to control mice, at 
each of the three test sites. Log-rank test was used to calculate p-values for differences between treated and control mice.
Table 1  Median survival values (in days) for male and female control mice
Site Sex Median ± standard error (N)
TJL Female 858 ± 7 (93)
UM Female 909 ± 4 (86)
UT Female 876 ± 4 (96)
TJL Male 781 ± 7 (125)
UM Male 876 ± 8 (106)
UT Male 739 ± 7 (119)
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of husbandry, diet, or other nongenetic variables among the
three test sites.
 
Assessment of the effects of gender on plasma NDGA, 
aspirin, and salicylic acid
 
To see whether gender differences in the effects of NDGA and
aspirin on survival resulted from gender differences in drug
disposition, we assessed drug levels in male and female mice
given free access for 4 weeks to diets that contained either one
of two different doses of aspirin or one of two different doses
of NDGA. The results for NDGA are shown in Fig. 4. Median
















 0.0055) in males as compared to female mice fed




 food), the dose of NDGA used in
the survival study reported here. Additionally, males fed the
high dose diet (5 g kg
 
–1 food) had a significantly higher (Mann–
Whitney U = 4.5, p = 0.001) median concentration of plasma
NDGA than females in that treatment group.
Results of the aspirin feeding study are shown in Fig. 5 and
Fig. S2. There was a wide range of plasma aspirin and
salicylic acid values in both male and female mice, which may
reflect the genetic heterogeneity in this population, or may
reflect differences in the time between when each mouse last
ate and when blood was taken for analysis. There were no
significant differences in aspirin or salicylic acid levels between
males and females at either tested dose as shown in Fig. S2.
However, as shown in Fig. 5, males had a significantly lower
ratio of salicylic acid/aspirin at each dose (high-dose, Mann–
Whitney U = 1.0, p = 0.0002; low-dose, Mann–Whitney U = 8.000,
p = 0.0055), consistent with the idea that conversion of aspirin
to its less active metabolite salicylic acid may occur more rapidly
in females than in males.
Discussion
Our results showed that NDGA and aspirin each increase survival
in male UM-HET3 mice, but not in females. The body weight
data (Miller et al., 2007) suggest that these beneficial effects
are not mediated by caloric restriction. Previous studies of
agents reported to extend rodent lifespan when added in food
(see Schneider & Reed, 1985; Schneider & Miller, 1998, for
reviews) have been criticized frequently for small sample sizes,
use of short-lived control groups, or the lack of information
about a colony’s infectious status; and none, as far as we can
determine, has ever been replicated either at the original test
site or by a second laboratory group. Nearly all prior studies have
used isogenic animal groups, raising the possibility that positive
results might reflect strain-specific idiosyncrasies that would not
be reproducible in other genetic stocks. Our own results, using
genetically heterogeneous mice, three specific pathogen-free
vivaria, and a relatively long-lived set of control mice, may provide
a better foundation for future replication.
Fig. 3 Survival plots for control (untreated) males 
(left panel) and females (right panel) showing the 
comparison among the three test sites. Log-rank 
test was used to calculate p-values for differences 
among the three test sites.
Fig. 4 Nordihydroguaiaretic acid (NDGA) levels in plasma of young UM-HET3 
mice after 4 weeks of consumption of food containing NDGA at either 
2.5 g per kg food (‘low dose’, upper panel) or 5 g per kg food (‘high dose’, 
lower panel). Each symbol represents an individual mouse, and median 
levels are shown by horizontal lines. Statistical significance was evaluated 
by the Mann–Whitney test.
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We were only able to test each compound at a single dose,
because of cost considerations, and the dose selected was in
each case based on limited previous experience with that agent
in rodents. It is possible therefore that different results, including
a larger positive effect on survival, might have been seen at doses
different from those used in this study. In planned Phase II testing
of NDGA and aspirin, the survival studies will be repeated with
multiple doses of each agent.
Our interim report (Miller et al., 2007) found a positive effect
of NDGA on male survival during the first half of the lifespan,
but there are precedents in which an intervention, such as
exercise (Holloszy, 1993), has been shown to increase median
lifespan or some other index of mortality risks in young and
middle-aged adults, without any effect on maximum lifespan
or an equivalent index of survival among the oldest test subjects.
Therefore, we assessed the effect of NDGA and aspirin on
the proportion of mice that live past the age at which 90% of
the population has died using a quantile test (Wang et al.,
2004). Although the proportion of mice alive at 90% mortality
was greater in the NDGA and aspirin groups as compared to
the control group, the effects were not statistically significant
(p = 0.12 and p = 0.16, respectively). Therefore, we are unable
to conclude at this stage that either treatment had an effect
on maximum lifespan at the dose used. If NDGA and/or aspirin
do indeed modulate the rate of aging or the risks of specific
lethal illnesses, it is entirely possible that the optimal benefit,
including perhaps a change in probability of survival to the 90th
percentile, might be seen at doses higher or lower than those
used in this initial study.
Although our experimental design did not include sufficient
animals to allow us to detect small intervention effects at each
of the three test sites, we note from Fig. 2 that the effects of
aspirin and of NDGA were strongest at the two sites where
control males had the shortest lifespan (see Fig. 3). Significant
differences among the three sites in survival of control males
have also been seen in a separate cohort of control mice being
used for comparison to other ITP interventions initiated in 2005
(‘Cohort 2’ mice; data not shown), with UM males again showing
lowest mortality risks in the first half of the lifespan. The site-
specific differences seem unlikely to reflect systematic effects
on mouse health, in that there were no differences among sites
in survival of control females in either Cohort 1 (Fig. 3) or Cohort
2 (not shown). Median lifespan for females at all three ITP sites
is similar to that found in previous lifespan studies of UM-HET3
mice (all conducted at UM; see Miller et al., 2007, for citations).
Median lifespan for ITP males at UM is slightly higher than in
any of the three previous studies, but median lifespan for UT
and TJL males is somewhat lower than in the historical controls
conducted at UM. We suspect that these differences in control
male life tables reflect differences among the sites in the specific
dietary formulations administered to the breeders used to
produce UM-HET3 test mice at each site, or to the formulations
to which the test mice were exposed between weaning and
transfer to the drug-containing test diets at age 4 months (aspirin,
NFP, 4-OH-PBN, and control groups) or at 9 months (NDGA
groups). The diets used for breeders and weanlings (prior to
drug exposure) differ in fat content (4.5–6.5%), supplemental
levels of thiamine and other heat-sensitive vitamins, protein
content (18–24%) and source of protein (e.g. fish, beet, or pork
meal). Control and drug-exposed mice at the UM site were
routinely and significantly smaller than those at the other two
sites throughout adult life, for both males and females, and
these differences could well reflect lasting influences of differences
in dietary regimen on breeders, weanlings, or both. It is also
possible that other site-specific factors, such as minor differences
in water quality, noise level, ventilation details, extraneous odors,
cage-changing frequency, etc., might contribute to site-specific
differences in survival of male (but not of female) mice. Starting
with Cohort 4 (born in 2007), the three ITP sites have adopted
a uniform protocol for diet composition at all stages of the test
process, including diets for breeder mice and for test mice prior
to drug administration. Replicate studies, at the ITP test sites and
at other facilities, will be needed to determine whether the present
findings on aspirin and NDGA are robust and reproducible in
multiple colonies.
The observation that NDGA or aspirin increased survival in
males, but not females, could be accounted for by gender
Fig. 5 Ratio of salicylic acid to aspirin in plasma of young UM-HET3 mice 
after 4 weeks of consumption of food containing aspirin at either 
20 g per kg food (‘low dose’, upper panel) or 60 g per kg food (‘high dose’, 
lower panel). Each symbol represents an individual mouse, and median 
levels are shown by horizontal lines. Statistical significance was evaluated 
by the Mann–Whitney test.
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differences in steady-state levels and/or in metabolizing the
drugs. We conducted a 4-week study in which male and female
mice were fed diets containing two different doses of each com-
pound; the original dose used in the survival studies reported
here and a higher dose. The results for NDGA revealed that
males in each dosage group had higher median plasma con-
centrations of NDGA than females; this difference was twofold
at the original dose used in the survival studies. Thus, it is plau-
sible that NDGA may have extended the lifespan of male mice
and not females because of differences between the sexes in
peak or average NDGA serum concentrations. More definitive
conclusions await Phase II studies in which the effects of a
higher dose of NDGA on survival in male and female mice will
be studied. Similarly, the results of feeding aspirin to male and
female mice provided evidence for gender differences in aspirin
metabolism. Thus, there was a two- to threefold higher ratio
of salicylic acid metabolite to aspirin in female mice fed either
dose of aspirin, indicating that a greater proportion of the
ingested aspirin is converted to salicylic acid in females as
compared to males. Aspirin’s principal mechanism of action is
to inhibit the activity of COX-1 and 2. Aspirin is 100-fold more
potent than salicylic acid in inhibiting COX-1 activity and two-
fold more potent than salicylic acid in inhibiting COX-2 (Mitchell
et al., 1993). Thus, a higher ratio of salicylic acid to aspirin in females
would be consistent with a reduced therapeutic effect of aspirin
in females. This result is consistent with that of human studies
of the effects of aspirin on the risk of myocardial infarction that
indicate females are less responsive to aspirin (Yerman et al., 2007).
This may explain why aspirin increased survival in male mice and
not female mice. More comprehensive pharmacokinetic studies
and feeding a higher dose of aspirin, in addition to the original
dose, in planned Phase II studies, will allow for more definitive
conclusions.
The present results are consistent with previous reports that
NDGA increases lifespan in both insects and mammals. Thus,
NDGA has been reported to increase lifespan in fruit flies, mos-
quitoes, and rats (Buu-Hoi & Ratsimamang, 1959; Miquel et al.,
1982; Richie et al., 1986). Several properties of NDGA may
contribute to its beneficial effects on lifespan. For example,
NDGA may act to prevent deleterious effects of aging on the
brain. Thus, it has been reported to extend the survival of a
mouse model of amyotrophic lateral sclerosis, the G93A SOD1
mutant mouse (West et al., 2004). Expression of 5-lipoxygenase
is elevated with age and has been proposed to play a role in
the pathobiology of aging-associated neurodegenerative diseases
(Manev et al., 2000; Qu et al., 2001). Indeed, NDGA has been
reported to be effective in preventing neuronal death and
cognitive deficits resulting from forebrain ischemia-reperfusion
injury (Shishido et al., 2001). Moreover, it has been reported to
enhance glucose clearance and insulin sensitivity in a rat diabetes
model (Reed et al., 1999). In the same study, it was reported to
drastically reduce serum triglycerides (Reed et al., 1999), which
may relate in part to NDGA’s reported ability to block fatty acid
synthesis in adipocytes through inhibition of fatty acid synthase
and to inhibit lipoprotein lipase (Park & Pariza, 2001; Li et al.,
2005). In numerous studies, NDGA has been reported to have
anticancer activity through its action as a 5-lipoxygenase inhibitor
(e.g. McDonald et al., 2001; Hoferova et al., 2004; Nony et al.,
2005). It has also been reported to suppress growth of breast
cancer cells through inhibition of the function of two receptor
tyrosine kinases, the insulin-like growth factor receptor (IGF-1R),
and the c-erbB2/HER2/neu (HER2/neu) (Youngren et al., 2005).
The effect of aspirin on lifespan in mice in the present study
is consistent with reports of numerous epidemiological studies
showing that aspirin use reduces the risk of mortality from a
variety of diseases in humans, including colon cancer, prostate
cancer, and cardiovascular disease (e.g. Johnson et al., 2002; Jacobs
et al., 2005; Lim et al., 2007; Chan et al., 2008). Recently, aspirin
was reported to activate the NF-kappaB signaling pathway and
induce apoptosis in two in vivo models of human colorectal
cancer (Stark et al., 2007). Aspirin also normalized blood pressure
in a rat model of hypertension (Tuttle et al., 1988). Furthermore,
it reportedly improved learning of a spatial memory task in old
rats (Smith et al., 2002). Interestingly aspirin use was reported
to be associated with increased survival in extreme old age in
humans. Aspirin use was associated with increased survival in
a 5-year follow-up study of subjects in the Finnish Centenarian
Study (Agüero-Torres et al., 2001). The authors concluded that
the increased survival was probably not attributable simply to
the anti-atherogenic effects of aspirin, because the aspirin
group had significantly more cardiovascular disease than the
non-aspirin users.
Both NDGA and aspirin have antioxidative effects and anti-
inflammatory properties in addition to the other properties
already discussed (Harper et al., 1999; Shi et al., 1999). NDGA,
for example, is a potent antioxidant and has anti-inflammatory
activity by inhibiting leukotriene synthesis (Harper et al., 1999;
West et al., 2004). Aspirin potently inhibits oxidative damage,
most likely through scavenging the hydroxyl radical and has
anti-inflammatory actions by inhibiting prostaglandin synthesis
(Shi et al., 1999; Vane, 2000). It is noteworthy that the compounds
studied in Cohort I have either anti-inflammatory properties
(nitroflurbiprophen), antioxidant properties (4OH-PBN), or both
(NDGA and aspirin). Of the four compounds tested, only those with
both anti-inflammatory action and antioxidant activity extended
lifespan in males. Thus, the combination of antioxidant activity with
anti-inflammatory effects may be important in the positive results
seen from these two interventions in our initial Phase I study.
The effects of NDGA and aspirin on our measure of extreme
longevity, i.e. proportion surviving at the start of the final survival
decile, did not reach statistical significance (p = 0.12 and p =
0.16, respectively). It will be interesting to see if greater effects
are seen in follow-up studies of these agents at higher or lower
doses. Analysis of the effects of NDGA and aspirin on other indices
of age-dependent change, including data on terminal pathology,
incidence of nonlethal lesions (e.g. cataracts), and the pace of
functional changes (e.g. loss of immune response and muscle
strength) will all be needed to reach an inference as to whether
the effects of NDGA and aspirin on survival reflect a general effect
on aging and age-sensitive traits, or instead merely a deceleration
Effect of aspirin and NDGA on lifespan, R. Strong et al.
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of specific forms of lethal disease. Currently, we are planning
follow-up (‘Phase II’) studies that will include evaluations of the
effects of additional doses of aspirin and NDGA on multiple
markers of health in middle-aged mice, including analyses of
central nervous system function, metabolic rate, insulin and
IGF-1 sensitivity, IGF-I sensitivity, hematopoietic stem cells, DNA
strand breaks, body composition, bone mineral density, measures
of oxidative stress, T-cell subsets, collagen cross-linking, lens
turbidity, and early signs of neoplastic and degenerative illnesses.
Evaluations of possible modes of action of NDGA and aspirin,
including measurements of hormonal, oxidative, and metabolic
indices could help to test specific hypotheses about NDGA- and
aspirin-sensitive pathways relevant to the aging process and
pathogenesis of late-life illnesses. Studies of other compounds
with structures or pharmacologic profiles similar to NDGA and
aspirin also could be informative. Our data also provide a rationale
for evaluation of NDGA and aspirin effects on mortality risks in
other varieties of mice and potentially for parallel studies using
short-lived primates. Finally, the effects of NDGA and aspirin
on long-lived mice, for example mice on calorically restricted
diets, or dwarf mutants, could help to determine whether the
pathways by which NDGA and aspirin affect survival may overlap
with those involved in other models of lifespan extension in mice.
Experimental procedures
Mouse production, maintenance, 
and estimation of lifespan
UM-HET3 mice were produced at each of the three test sites.
The mothers of the test mice were CByB6F1/J, JAX stock #100009,
whose female parents are BALB/cByJ and whose male parents
are C57BL/6J. The fathers of the test mice were C3D2F1/J, JAX
stock #100004, whose mothers are C3H/HeJ and whose fathers
are DBA/2J. The first litter from each breeding cage was discarded,
so that all of the experimental animals would be the product
of a second or subsequent pregnancy. This decision was made
to avoid the possibility that mice born to primiparous dams might
receive inferior nutrition or maternal care compared to offspring
from subsequent pregnancies. Each test site enrolled approximately
equal numbers of weanlings each month over a 6-month period.
Mice were weaned into same-sex cages (3 males or 4 females/cage)
at the age of 19–21 days. Sires were not separated from pregnant
dams during the period of pregnancy to allow subsequent
impregnation at postpartum estrous. Mice did not receive ear
punches or toe clips or other identifying marks at weaning. Each
site used diets based on the NIH-31 standard. For breeding cages,
UM used Purina 5008 (Purina diets: Purina, St. Louis, MO, USA),
UT used Teklad 7912 (Teklad diets: Harlan Teklad, Madison, WI,
USA), and TJL used Purina 5K52. For weanlings prior to
4 months of age, UM used Purina 5001, UT used Teklad 7912,
and TJL used Purina 5LG6.
Mice were housed in plastic cages with metal tops, using
corn-cob bedding, specifically 1/4 inch Bed O’Cobs, produced
by The Andersons (Maumee, OH, USA). Mice were given free
access to water, acidified (pH 2.5–2.7) by addition of hydrochloric
acid, using water bottles rather than an automated watering
system. Mice were housed in ventilated cages, and were trans-
ferred to fresh cages every 14 days, except that at UT mice were
transferred to fresh cages every 7 days. Temperature was main-
tained within the range of 21 °C to 23 °C.
At the age of 42 days, each cage was assigned to a control
or test group by use of a random number table. Each mouse
was then briefly anesthetized by isoflurane inhalation admini-
stered either by nose cone or by an instrument designed for
small animal anesthesia. Measures were taken of weight, body
length, and tail length; and an electronic ID chip was implanted
by sterile syringe beneath the dorsal skin between the shoulder
blades, after which the wound was closed by a drop of superglue
(Loctite gel, purchased locally, or Nexaband S/C, purchased
from Abbott Laboratories, North Chicago, IL, USA). UM and UT
used chips purchased from AVID Microchip ID Systems (Folsom,
LA, USA; Catalog AVID3002); TJL used chips purchased from
Locus Technology (Manchester, MD, USA; catalog 1D-100A).
A portion of the distal tail (1 cm) was taken and frozen for later
analysis of DNA polymorphisms, after which the mouse was
permitted to awaken from the anesthesia. The duration of
anesthesia was approximately 1–2 min.
Mice received control diet until the age of 4 months, after
which mice in the control group received Purina 5LG6 at all
three sites and mice in the NFP, 4-OH-PBN, and aspirin groups
received Purina 5LG6 containing these additives. Mice in the
NDGA group started receiving 5LG6 supplemented with NDGA
at the age of 9 months.
At the age of 7 months, a subset of the mice (100 controls
plus 50 of each test group at each site) were evaluated for
activity, using a test in which each mouse is housed individually
in a standard mouse cage for 50 h, while a computer records
episodes of ambulation or movement in place. This test was
repeated at the age of 18 months, for each live mouse that had
been previously tested. Three weeks after the activity test, a
blood sample was obtained from each mouse that had been
tested for activity; these samples were used for analyses of T-cell
subsets and hormone levels that will be reported elsewhere.
Details of the methods used for health monitoring were
provided in Miller et al. (2007); in brief, each of the three
colonies was evaluated four times each year for infectious
agents, including pinworm. All such tests were negative throughout
the entire study period.
Removal of mice from the longevity population
As described in detail in Miller et al. (2007), mice were removed
from the study because of fighting (36 mice), or accidental
death, typically during chip implantation or chip failure (26 mice),
or because they were used for another experimental purpose, such
as testing for blood levels of a test agent (51 mice). For survival
analyses, all such mice were treated as alive at the date of their
removal from the protocol, and lost to follow-up thereafter. These
mice were not included in calculations of median longevity.
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Estimation of age at death (lifespan)
Mice were examined at least daily for signs of ill health. Mice were
euthanized for humane reasons if so severely moribund that
they were considered, by an experienced technician, unlikely to
survive for more than an additional 48 h. A mouse was considered
severely moribund if it exhibited more than one of the following
clinical signs: (i) inability to eat or to drink; (ii) severe lethargy,
as indicated by reluctance to move when gently prodded with
a forceps; (iii) severe balance or gait disturbance; (iv) rapid
weight loss over a period of 1 week or more; or (v) an ulcerated
or bleeding tumor. The age at which a moribund mouse was
euthanized was taken as the best available estimate of its
natural lifespan. Mice found dead were also noted at each daily
inspection.
Control and experimental diets
TestDiet Inc. (Richmond, IN, USA) prepared batches of Purina
5LG6 food containing each of the test substances, as well as
control diet batches, at intervals of approximately 4 months, and
shipped each batch of food at the same time to each of the three
test sites. NDGA was purchased from Cayman Chemicals (Ann
Arbor, MI, USA) and was mixed with chow at a concentration of
2500 milligrams of NDGA per kilogram of food. Nitroflurbiprofen
was obtained from NicOx Research Institute (Milan, Italy) and
used at a dose of 200 mg NFP per kilogram of food. Aspirin was
obtained from a local supplier and used at a dose of 21 mg per
kg of food. 4-OH-PBN was synthesized in the laboratory of
Robert Floyd and used at a dose of 350 mg per kilogram of food.
On the assumption that each mouse weighs 30 g and consumes
5 g food/day, the estimated daily doses of these agents would
be NDGA 417; NFP 33; 4-OH-PBN 53, and aspirin 3.3 mg kg–1
body weight day–1.
Measurement of concentrations of NDGA, aspirin, 
and salicylic acid in plasma
Male mice (9 per condition) and female mice (8 per condition)
were treated for 4 weeks at the UM site with two different doses
of aspirin or NDGA administered in the diet. Doses of NDGA
were 2.5 g kg–1 food (low dose, same as for the current study)
and 5 g kg–1 (high dose). Doses of aspirin were 20 mg kg–1 food
(low dose, same as for the current study) and 60 mg kg–1 food
(high dose). Concentrations of aspirin and NDGA in food were
verified by high-performance liquid chromatography (HPLC)
analysis. Animals had free access to food and water 24 h per
day. At the end of the treatment period, blood samples (200–
300 μL each) were obtained from the tail vein. Samples were
taken at approximately 09:00 h, 3 hours after the lights come
on in the animal facility. Blood samples were centrifuged to
pellet the cell and the plasma supernatant was carefully
removed. The tubes were shipped on dry ice to the UT site
and stored frozen at –80 °C until assayed for NDGA, aspirin,
and salicylic acid.
Measurement of NDGA
NDGA was quantified in mouse plasma using HPLC with UV
detection. Briefly, 200 μL of calibrators and unknown samples
were mixed with 10 μL of 100 μg mL–1 flurbiprofen (internal
standard) and 2 mL of 50:50 acetonitrile : methanol. The samples
were vortexed vigorously and then centrifuged at 1500 g for
15 min. Supernatants were transferred to glass test tubes and
dried to residue under a gentle stream of nitrogen. The residues
were redissolved in 250 μL of mobile phase and then filtered
using a microfilterfuge tube. Then, 150 μL of the final samples
were injected into the HPLC. The ratios of the peak area of
NDGA to that of the internal standard were compared against
a linear regression of calibrators at concentrations of 0, 50, 100,
500, and 1000 ng mL–1 to quantify NDGA in the samples. NDGA
concentration in blood or plasma was reported in ng mL–1.
The HPLC system consisted of an Alltima C18 column (4.6 ×
150 mm, 5 μm) (Grace, Deerfield, IL, USA), Waters 2487 UV
detector, Waters 717 autosampler, Waters 515 HPLC pump
(Milford, MA, USA). The mobile phase was 35% acetonitrile,
64.9% Milli-Q water (Millipore Corp., Billerica, MA, USA), and 0.1%
phosphoric acid (pH 2.5). The flow rate of the mobile phase was
1.5 mL min–1 and the wavelength of absorbance was 214 nm.
Measurement of aspirin and salicylic acid
Aspirin and salicylic acid were quantified in mouse plasma using
HPLC with UV detection. The HPLC system and settings were the
same as that described for measurement of NDGA except that
the mobile phase was 8% methanol, 6% acetonitrile, 3.3 mM
phosphate in Milli-Q water (pH 2.5). Briefly, 200 μL of calibrators
and unknown samples were mixed with 700 μL of EDTA solution,
10 μL of 500 μg mL–1 homovanillic acid (internal standard), 500 μL
of 1 M HCl, and 2 mL of water-saturated ethyl acetate. The
samples were vortexed vigorously, shaken for 15 min, and then
centrifuged at 1500 g for 15 min. Next, 1.7 mL of the supernatants
were transferred to glass test tubes and dried to residue under
a gentle stream of nitrogen. The residues were redissolved in
200 μL of mobile phase and then filtered using a microfilterfuge
tube. Then, 150 μL of the final samples were injected into the
HPLC apparatus. The ratios of the peak area of aspirin and
salicylic acid to those of the internal standard were compared
against a linear regression of calibrators at concentrations of 0,
250, 500, 1000, and 2000 ng mL–1 to quantify aspirin and salicylic
acid in the samples. Aspirin and salicylic acid concentrations in
blood or plasma were reported in ng mL–1.
Statistical methods
Each mouse originally entered into the study was, at the time
of analysis, considered to be in one of two categories: either
dead (from natural causes), or censored. Mice were considered
to be censored at the age at which they were no longer subjected
to the mortality risks typical of unmanipulated mice. In some
cases, this was because the mouse was removed because of
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fighting; in other cases, mice died as the result of an accident
(e.g. death when anesthetized for implantation of a radio-emitting
chip). In still other cases, mice were considered censored on the
day in which they received an experimental treatment (such as
blood sampling or injection with an inflammatory agent) to
which the control mice were not exposed. Kaplan–Meier analysis
and log-rank comparisons among groups consider censored
mice to be lost from follow-up on the day at which they were
removed from the longevity protocol. There were no mice
remaining alive at the time of the analyses reported here.
Unless stated otherwise, all significance tests about survival
effects are based upon the two-tailed log-rank test at p < 0.05,
stratified by test site, with censored mice included up until their
date of removal from the longevity population. Other statistical
tests are described in the text; all p-values were two-tailed.
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Fig. S1 Survival plots for female mice treated with nordihydro-
guaiaretic acid (NDGA; upper left), aspirin (upper right), nitro-
flurbiprofen (NFP; lower left) or 4-OH-PBN (lower right.) Each
symbol represents an individual mouse dying at the age indicated.
There were no significant differences between treated and control
groups using the log-rank test.
Fig. S2 Effects of gender on aspirin and salicylic acid levels in
plasma of young UM-HET3 mice after 4 weeks of consumption
of food containing aspirin at either 20 mg per kg food (‘low dose’,
right panels) or 60 mg per kg food (‘high dose’, left panels).
Each symbol represents an individual mouse, and median values
are shown by horizontal lines. The p-values show the outcomes
of Mann–Whitney tests for differences between males and females.
Top row: aspirin levels. Middle row: salicylic acid levels.
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